[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Virax Biolabs Group Limited (VRAX)

Virax Biolabs Group Limited (VRAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,749
  • Shares Outstanding, K 797
  • Annual Sales, $ 10 K
  • Annual Income, $ -5,020 K
  • EBIT $ 0 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.35
  • Price/Sales 248.38
  • Price/Cash Flow N/A
  • Price/Book 0.09

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.75
  • Number of Estimates 1
  • High Estimate $-1.75
  • Low Estimate $-1.75
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.57 +51.75%
on 07/01/26
13.19 -70.43%
on 07/09/26
-0.03 (-0.64%)
since 06/16/26
3-Month
2.57 +51.75%
on 07/01/26
13.34 -70.76%
on 05/18/26
+0.11 (+2.97%)
since 04/16/26
52-Week
2.50 +56.00%
on 04/10/26
28.50 -86.32%
on 07/21/25
-19.13 (-83.06%)
since 07/16/25

Most Recent Stories

More News
Virax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply Agreement

LONDON , July 16, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), a biotechnology company focused on immune response detection, T cell immune profiling...

VRAX : 3.90 (+13.04%)
Virax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

LONDON , July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) today closed its previously announced exercise of certain outstanding preferred investment...

VRAX : 3.90 (+13.04%)
Virax Biolabs Stock Skyrockets 100% on Exclusive Distribution Agreement

Virax stock soars on a commercial supply agreement with Fosun Diagnostics. But disciplined investors are cautioned against chasing the momentum in VRAX shares.

VRAX : 3.90 (+13.04%)
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds

LONDON , July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX) announced today that it has entered into a definitive agreement for the immediate exercise...

VRAX : 3.90 (+13.04%)
Virax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun Diagnostics

LONDON , July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered...

VRAX : 3.90 (+13.04%)
Virax Biolabs Reports Positive Early Clinical Data for ViraxImmuneâ„¢ in Long COVID and Related Post-Acute Infection Syndromes

LONDON , May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmuneâ„¢, its blood-based...

VRAX : 3.90 (+13.04%)
Avalon Advanced Materials and Virax Biolabs Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

ORLANDO, FL / ACCESS Newswire / May 15, 2026 / RedChip Companies will air interviews with Avalon Advanced Materials Inc. (OTCQB:AVLNF)(TSX:AVL) and Virax Biolabs Group Limited (Nasdaq:VRAX) on the RedChip...

AVLNF : 0.0336 (+7.01%)
AVL.TO : 7.44 (-6.88%)
VRAX : 3.90 (+13.04%)
Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders

Virax Biolabs is advancing a focused strategy centered on ViraxImmuneâ„¢ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its...

VRAX : 3.90 (+13.04%)
Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation

LONDON , March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved...

VRAX : 3.90 (+13.04%)
Virax Biolabs Group Limited Announces Closing of $5 Million Private Placement

LONDON , Dec. 4, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research...

VRAX : 3.90 (+13.04%)

Business Summary

Virax Biolabs Group Limited is a biotechnology company focused on the prevention, detection, and diagnosis of viral diseases as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus. Virax Biolabs Group Limited is based in London, United Kingdom.

See More

Key Turning Points

3rd Resistance Point 4.85
2nd Resistance Point 4.49
1st Resistance Point 4.19
Last Price 3.90
1st Support Level 3.53
2nd Support Level 3.17
3rd Support Level 2.87

See More

52-Week High 28.50
Fibonacci 61.8% 18.57
Fibonacci 50% 15.50
Fibonacci 38.2% 12.43
Last Price 3.90
52-Week Low 2.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.